Background: Depressive and anxiety symptoms are prevalent among older adults and associated with increased dementia risk. In healthy older adults, higher step counts are associated with fewer depressive and anxiety symptoms; whether this holds in individuals with cognitive concerns (subjective cognitive decline [SCD] or mild cognitive impairment [MCI]) is unknown. In a randomised controlled trial, the 12-month APPLE-Tree group psychosocial lifestyle intervention produced small cognitive improvements but no change in step count. Objective: To test whether step count was associated with depressive and anxiety symptoms (cross-sectionally and over 24 months), and whether APPLE-Tree increased step count in participants with clinical anxiety or depression. Methods: We examined cross-sectional and longitudinal (12- and 24-month) associations between step count (two-week average from wrist-worn wearables) and depressive and anxiety symptoms (Hospital Anxiety and Depression Scale) using adjusted linear regressions, with a mediation analysis of self-perceived mobility. We also tested whether the intervention increased step count in those with baseline clinical anxiety or depression. Findings: We included 629 of 746 trial participants at baseline, of whom 376 contributed 12-month and 215 24-month data.
Background: Depressive and anxiety symptoms are prevalent among older adults and associated with increased dementia risk. In healthy older adults, higher step counts are associated with fewer depressive and anxiety symptoms; whether this holds in individuals with cognitive concerns (subjective cognitive decline [SCD] or mild cognitive impairment [MCI]) is unknown. In a randomised controlled trial, the 12-month APPLE-Tree group psychosocial lifestyle intervention produced small cognitive improvements but no change in step count. Objective: To test whether step count was associated with depressive and anxiety symptoms (cross-sectionally and over 24 months), and whether APPLE-Tree increased step count in participants with clinical anxiety or depression. Methods: We examined cross-sectional and longitudinal (12- and 24-month) associations between step count (two-week average from wrist-worn wearables) and depressive and anxiety symptoms (Hospital Anxiety and Depression Scale) using adjusted linear regressions, with a mediation analysis of self-perceived mobility. We also tested whether the intervention increased step count in those with baseline clinical anxiety or depression. Findings: We included 629 of 746 trial participants at baseline, of whom 376 contributed 12-month and 215 24-month data. At baseline, higher step counts were associated with fewer depressive symptoms ({beta} = -0.11, 95% CI -0.17 to -0.05, p < 0.001) but, counter to our hypothesis, more anxiety symptoms ({beta} = 0.12, 95% CI 0.06 to 0.19, p = 0.003). Over two years, change in step count was not associated with change in depressive or anxiety symptoms (all p [≥] 0.12). Self-perceived mobility problems mediated the association between step count and depressive but not anxiety symptoms. The intervention did not change step count in those with clinical anxiety or depression. Conclusions: This provides the first evidence in older adults with cognitive concerns that higher step counts are associated with fewer depressive but more anxiety symptoms. This may reflect heterogeneity of a population that includes those with prodromal dementia and cognitive health anxiety. Step count did not predict symptoms over time. Clinical implication: Step count may help distinguish anxiety and depressive symptoms in people presenting with cognitive concerns, or underlying reasons for cognitive concerns among those with functional cognitive disorders.